The significance of ribosomal P protein auto-antibodies in systemic lupus erythematosus patients assayed by peptide-antigen based enzyme-linked immunosorbent assay method

YE Ping,XU Gui-fang,CHEN Xiao-Xiang,YE Shuang,LU Yu,CHEN Shun-le
2006-01-01
Abstract:Objective To study the diagnosis significance of anti-ribosomal P antibody in systemic lupus erythematosus (SLE). Method Indirect enzyme-linked immunosorbent (ELISA) assay based on 3 ribsomal P epitope peptides (Pharmarcia) and immunobloting (IBT) method were used to assay anti-ribosomal P antibody. One hundred SLE patients were recruited as study group. Another 100 non-SLE patients were used as control group, which included 45 rheumatoid arthritis patients, 22 ankylosing spondylitis patients, 8 Sj?觟gren syndrome patients, 6 dermotomyositis/polymyositis patients, 9 other autoimmune diseases patients and 10 healthy people. Results The positive cutoff value was determined as 1.258 by the absorbance (A) value of mean plus 3 standard deviation. The positive rate of SLE group was 14% (14 in 100), and the positive rate of non-SLE group was 1%, and there was significant difference between these two groups (P<0.001). There was also a good correlation between ELISA method and IBT method. Conclusion The data shows that antigen peptide based ELISA and traditional IBT method is well correlated. Anti-ribosomal P antibody, which is a specific autoantibody in SLE, has high value in diagnosis. The data has shown a relatively low positive rate in this Chinese cohort than other reported data. And there is no correlation between anti-ribosomal P and clinical manifestations, such as central nervous system involvement, lupus nephritis, arthritis, rash, and disease activity (SLEDAI). There is no correlation with other autoantibodies.
What problem does this paper attempt to address?